Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 42, Issue 1, 2015, Pages 1-18

  Chudasama, Vaishali L ^a   Zutshi, Anup ^b   Singh, Pratap ^b   Abraham, Anson K ^b   Mager, Donald E ^a   Harrold, John M ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b PFIZER INC   (United States)

Author keywords

Asthma; Bispecific antibodies; Pharmacodynamics; Pharmacokinetics; Systemic lupus erythematous; Ulcerative colitis

Indexed keywords

BISPECIFIC ANTIBODY; PROTEIN BINDING;

ANTIBODY SPECIFICITY; ASTHMA; BINDING SITE; BIOLOGICAL MODEL; BLOOD; COLITIS, ULCERATIVE; COMPUTER SIMULATION; DRUG DESIGN; HUMAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; PREDICTIVE VALUE; TISSUE DISTRIBUTION;

ANTIBODIES, BISPECIFIC; ASTHMA; BINDING SITES; COLITIS, ULCERATIVE; COMPUTER SIMULATION; DRUG DESIGN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, BIOLOGICAL; ORGAN SPECIFICITY; PREDICTIVE VALUE OF TESTS; PROTEIN BINDING; TISSUE DISTRIBUTION;

EID: 84920815613     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-014-9401-1     Document Type: Article

References (54)

1. Fagete S, Fischer N (2011) Smarter drugs: a focus on pan-specific monoclonal antibodies. BioDrugs 25:357–364
2. Holmes D (2011) Buy buy bispecific antibodies. Nat Rev Drug Discov 10:798–800
3. Baeuerle PA, Reinhardt C (2009) Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 69:4941–4944
4. Wang W, Wang EQ, Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84:548–558
5. Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507–532
6. Gibiansky L, Gibiansky E (2010) Target-mediated drug disposition model for drugs that bind to more than one target. J Pharmacokinet Pharmacodyn 37:323–346
7. Cyster JG, Ansel KM, Reif K, Ekland EH, Hyman PL et al (2000) Follicular stromal cells and lymphocyte homing to follicles. Immunol Rev 176:181–193
8. Ansel KM, Ngo VN, Hyman PL, Luther SA, Forster R et al (2000) A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406:309–314
9. Schiffer L, Kumpers P, Davalos-Misslitz AM, Haubitz M, Haller H et al (2009) B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE). Nephrol Dial Transplant 24:3708–3712
10. Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:515–548
11. Yang JH, Zhang J, Cai Q, Zhao DB, Wang J et al (2005) Expression and function of inducible costimulator on peripheral blood T cells in patients with systemic lupus erythematosus. Rheumatology (Oxford) 44:1245–1254
12. Beier KC, Hutloff A, Lohning M, Kallinich T, Kroczek RA et al (2004) Inducible costimulator-positive T cells are required for allergen-induced local B-cell infiltration and antigen-specific IgE production in lung tissue. J Allergy Clin Immunol 114:775–782
13. Lee WI, Zhu Q, Gambineri E, Jin Y, Welcher AA et al (2003) Inducible CO-stimulator molecule, a candidate gene for defective isotype switching, is normal in patients with hyper-IgM syndrome of unknown molecular diagnosis. J Allergy Clin Immunol 112:958–964
14. Warnatz K, Bossaller L, Salzer U, Skrabl-Baumgartner A, Schwinger W et al (2006) Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency. Blood 107:3045–3052
15. Lee HT, Shiao YM, Wu TH, Chen WS, Hsu YH et al (2010) Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. J Rheumatol 37:45–52
16. Her M, Kim D, Oh M, Jeong H, Choi I (2009) Increased expression of soluble inducible costimulator ligand (ICOSL) in patients with systemic lupus erythematosus. Lupus 18:501–507
17. Bosnjak B, Stelzmueller B, Erb KJ, Epstein MM (2011) Treatment of allergic asthma: modulation of Th2 cells and their responses. Respir Res 12:114
18. Beltran CJ, Candia E, Erranz B, Figueroa C, Gonzalez MJ et al (2009) Peripheral cytokine profile in Chilean patients with Crohn’s disease and ulcerative colitis. Eur Cytokine Netw 20:33–38
19. Baumgart DC, Carding SR (2007) Inflammatory bowel disease: cause and immunobiology. Lancet 369:1627–1640
20. Oh CK, Geba GP, Molfino N (2010) Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 19:46–54
21. Wills-Karp M, Finkelman FD (2008) Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal 1:55
22. Zurawski SM, Chomarat P, Djossou O, Bidaud C, McKenzie AN et al (1995) The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor. J Biol Chem 270:13869–13878
23. Milligan PA, Brown MJ, Marchant B, Martin SW, van der Graaf PH et al (2013) Model-based drug development: a rational approach to efficiently accelerate drug development. Clin Pharmacol Ther 93:502–514
24. Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ et al (2007) Model-based drug development. Clin Pharmacol Ther 82:21–32
25. Hu L, Hansen RJ (2013) Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies. J Pharm Sci 102:2898–2908
26. Mould DR, Sweeney KR (2007) The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 10:84–96
27. Stepensky D (2012) Local versus systemic anti-tumour necrosis factor-alpha effects of adalimumab in rheumatoid arthritis: pharmacokinetic modelling analysis of interaction between a soluble target and a drug. Clin Pharmacokinet 51:443–455
28. RITUXAN FDA Package Insert
29. Kawakami K, Taguchi J, Murata T, Puri RK (2001) The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 97:2673–2679
30. Harrold JM, Abraham AK (2014) Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment. J Pharmacokinet Pharmacodyn 41:141–151
31. Vugmeyster Y, DeFranco D, Szklut P, Wang Q, Xu X (2010) Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology. J Pharm Sci 99:1028–1045
32. Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M (2013) Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet 52:83–124
33. Zhang S, Liu C, Huang P, Zhou S, Ren J et al (2009) The affinity of human RANK binding to its ligand RANKL. Arch Biochem Biophys 487:49–53
34. Chen PC, DuBois GC, Chen MJ (1995) Mapping the domain(s) critical for the binding of human tumor necrosis factor-alpha to its two receptors. J Biol Chem 270:2874–2878
35. Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645–2668
36. Garg A, Balthasar JP (2007) Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34:687–709
37. Urva SR, Yang VC, Balthasar JP (2010) Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci 99:1582–1600
38. Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39:67–86
39. Abuqayyas L, Balthasar JP (2012) Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer. J Pharmacokinet Pharmacodyn 39:683–710
40. Shah DK, Betts AM (2013) Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs 5:297–305
41. Siddiqui S, Mistry V, Doe C, Stinson S, Foster M et al (2010) Airway wall expression of OX40/OX40L and interleukin-4 in asthma. Chest 137:797–804
42. West GA, Matsuura T, Levine AD, Klein JS, Fiocchi C (1996) Interleukin 4 in inflammatory bowel disease and mucosal immune reactivity. Gastroenterology 110:1683–1695
43. Vainer B, Nielsen OH, Hendel J, Horn T, Kirman I (2000) Colonic expression and synthesis of interleukin 13 and interleukin 15 in inflammatory bowel disease. Cytokine 12:1531–1536
44. Mould DR, Green B (2010) Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 24:23–39
45. Metz DP, Mohn D, Zhang M, Horan T, Kim H et al (2009) Defining dose–response relationships in the therapeutic blockade of B7RP-1-dependent immune responses. Eur J Pharmacol 610:110–118
46. Busse WW, Katial R, Gossage D, Sari S, Wang B et al (2010) Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 125(1237–1244):e1232
47. Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:633–659
48. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV et al (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323:1610–1614
49. Boulanger MJ, Bankovich AJ, Kortemme T, Baker D, Garcia KC (2003) Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130. Mol Cell 12:577–589
50. Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A et al (2007) Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol 25:107–116
51. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ et al (1986) Pharmacokinetics of monoclonal immunoglobulin G1, F(ab′)2, and Fab′ in mice. Cancer Res 46:3969–3978
52. Conlon PJ, Tyler S, Grabstein KH, Morrissey P (1989) Interleukin-4 (B-cell stimulatory factor-1) augments the in vivo generation of cytotoxic cells in immunosuppressed animals. Biotechnol Ther 1:31–41
53. Khodoun M, Lewis CC, Yang JQ, Orekov T, Potter C et al (2007) Differences in expression, affinity, and function of soluble (s)IL-4Ralpha and sIL-13Ralpha2 suggest opposite effects on allergic responses. J Immunol 179:6429–6438
54. Owen SG, Francis HW, Roberts MS (1994) Disappearance kinetics of solutes from synovial fluid after intra-articular injection. Br J Clin Pharmacol 38:349–355